Current and Future Directions in the Treatment of Pulmonary Neuroendocrine Tumors
This activity contains:
- CME/CPE/CNE-Certified Live Grand Rounds and Webinars
- Downloadable Slide Deck with Facilitator's Guide (a non-certified educational resource)
The goal of this activity is to provide the latest information on the diagnosis and management of pulmonary neuroendocrine tumors.
Pulmonary neuroendocrine tumors (NETs) are rare tumors, accounting for 1% to 2% of all lung neoplasms. Typical symptoms of pulmonary NETs include cough, respiratory infections, blood in expectorate, shortness of breath, and chest pain. Overproduction of histamine may cause face swelling, tearing, and flushing. On the other hand, overproduction of serotonin can result in diarrhea, decreased cardiac function, and asthma-like symptoms. Up to 20% and 70% of typical and atypical diseases are known to become metastatic. There are fewer treatment options for patients with unresectable disease, and the 5-year survival rate for patients with advanced disease is 27% with a median overall survival of 17 months.
The diagnosis of pulmonary NETs is challenging due to the rarity of the condition as well as heterogeneity of presentation. The treatment of localized disease relies on surgical resection of tumor, and for advanced/metastatic diseases systemic therapies can be used. However, there is no preferred treatment regimen for advanced disease, and clinicians may be unaware of optimized treatment options based on disease subtype. Healthcare professionals tending to patients with pulmonary NETs need to be aware of best practices in the diagnosis as well as treatment of the disease to provide optimal care to patients. In addition, recent evidence shows that patients with pulmonary NETs are mostly dissatisfied with the level of communication they receive from providers. Therefore, education about effective communication strategies between providers and patients is very pertinent to improving the quality of cancer care.
- Overview of pulmonary NETs
- Treatment strategies for localized pulmonary NETs
- Current and emerging therapies for advanced/metastatic pulmonary NETs
- Clinical patient case challenges
This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who manage patients with pulmonary neuroendocrine tumors.
At the conclusion of this activity, participants should be better able to:
- Summarize best practices for the timely diagnosis of pulmonary neuroendocrine tumors
- Identify effective strategies for treating localized pulmonary neuroendocrine tumors
- Describe treatment options for advanced/metastatic pulmonary NETs based on recent evidence and practice guidelines
- Identify effective strategies for shared decision making with patients that can improve quality of cancer care
|Edward M. Wolin, MD|
Director, Neuroendocrine Tumor Program
Montefiore Einstein Center for Cancer Care
Professor of Clinical Medicine, Department of Oncology
Albert Einstein College of Medicine
Bronx, New York
Pamela Kunz, MD
Diane Reidy-Lagunes, MD
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit (UAN 0592-0000-16-042-L01-P).
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Edward Wolin, MD||Edward Wolin, MD, reported a financial interest/relationship or affiliation in the form of Advisory board, Advanced Accelerator Applications, and Ipsen.|
|Pamela L. Kunz, MD|
Pamela L. Kunz, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee: Ipsen; Lexicon Pharmaceuticals, Inc.; Contracted research: Advanced Accelerator Applications; Dicerna Pharmaceuticals; Esanex Inc.; Genentech, Inc.; Ipsen; Lexicon Pharmaceuticals, Inc.; Merck & Co.; Oxigene, Inc.
|Diane Reidy-Lagunes, MD||Diane Reidy-Lagunes, MD reported a financial interest/relationship or affiliation in the form of Advisory board: Novartis Pharmaceuticals, Ipsen and Chiasma; Received research grant from: Novartis Pharmaceuticals and Ipsen.|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda Gracie-King, MS; Ronald Viggiani, MD; Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC, , and Stephanie Sutphin, PharmD hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is supported by an educational grant from Novartis Pharmaceuticals.
There is no fee for this educational activity.
This activity is provided by:
- 1.00 ANCC
- 1.00 Attendance
- 1.00 AMA PRA Category 1 Credit™